ATE323766T1 - Glykosylierte leptinzusammensetzungen und zugehörige verfahren - Google Patents

Glykosylierte leptinzusammensetzungen und zugehörige verfahren

Info

Publication number
ATE323766T1
ATE323766T1 AT00911784T AT00911784T ATE323766T1 AT E323766 T1 ATE323766 T1 AT E323766T1 AT 00911784 T AT00911784 T AT 00911784T AT 00911784 T AT00911784 T AT 00911784T AT E323766 T1 ATE323766 T1 AT E323766T1
Authority
AT
Austria
Prior art keywords
proteins
glycosylated
compositions
glycosylated leptin
leptin
Prior art date
Application number
AT00911784T
Other languages
English (en)
Inventor
Frances H Martin
Steven G Elliott
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE323766T1 publication Critical patent/ATE323766T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
AT00911784T 1999-02-12 2000-02-11 Glykosylierte leptinzusammensetzungen und zugehörige verfahren ATE323766T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24967599A 1999-02-12 1999-02-12

Publications (1)

Publication Number Publication Date
ATE323766T1 true ATE323766T1 (de) 2006-05-15

Family

ID=22944511

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00911784T ATE323766T1 (de) 1999-02-12 2000-02-11 Glykosylierte leptinzusammensetzungen und zugehörige verfahren

Country Status (11)

Country Link
EP (1) EP1151102B1 (de)
JP (1) JP4841037B2 (de)
AT (1) ATE323766T1 (de)
AU (1) AU781460B2 (de)
CA (1) CA2359840C (de)
CY (1) CY1107470T1 (de)
DE (1) DE60027409T2 (de)
DK (1) DK1151102T3 (de)
ES (1) ES2257287T3 (de)
PT (1) PT1151102E (de)
WO (1) WO2000047741A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
CA2459015A1 (en) * 2001-08-29 2003-03-13 The University Of Buckingham Use of leptin for infant with low birth weight for prevention of obesity
PT2219031E (pt) * 2001-10-22 2013-05-17 Amgen Inc Uso de leptina para tratamento de lipoatrofia humana e método para determinar predisposição ao referido tratamento
US7094579B2 (en) * 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
PT1587923E (pt) 2003-01-22 2011-12-07 Univ Duke Construções melhoradas para a expressão de polipéptidos lisossomais
CA2537340A1 (en) 2003-09-26 2005-04-07 Applied Research Systems Ars Holding N.V. Leader sequences for use in production of proteins
ES2566670T3 (es) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
WO2008067599A1 (en) * 2006-12-04 2008-06-12 Apollo Life Sciences Limited Isolated leptin and adiponectin molecules and chimeric molecules thereof
EP2170919B8 (de) 2007-06-12 2016-01-20 ratiopharm GmbH Verbessertes verfahren zur herstellung von nukleotidzuckern
JP2009126856A (ja) * 2007-11-28 2009-06-11 Fancl Corp 血中中性脂肪上昇抑制剤
CN102099048A (zh) 2008-05-21 2011-06-15 纽若泰兹公司 用于治疗与神经原纤维缠结有关的进行性认知障碍的方法
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
EP2352510A4 (de) 2008-11-04 2012-08-29 Neurotez Inc Leptinzusammensetzungen und verfahren zur behandlung von progressiven kognitiven störungen infolge der ansammlung von neurofibrillären bündeln und amyloid-beta
PL3241558T3 (pl) 2010-09-28 2021-08-30 Aegerion Pharmaceuticals, Inc. Wysoce rozpuszczalne leptyny
KR20220051197A (ko) 2012-05-17 2022-04-26 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
CN104822374A (zh) 2012-09-27 2015-08-05 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
SI3074033T1 (sl) 2013-11-26 2019-03-29 The Children's Medical Center Corporation Spojine za zdravljenje debelosti in postopki njihove uporabe
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
EP3220961B1 (de) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutische vitamin-d-konjugate
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US20180009869A1 (en) * 2016-07-08 2018-01-11 AskGene Pharma, Inc. Fusion Protein Comprising Leptin and Methods for Producing and Using the Same
BR112019004715A2 (pt) 2016-09-12 2019-07-16 Aegerion Pharmaceuticals Inc métodos para detectar anticorpos neutralizantes anti-leptina

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
CN1057534C (zh) * 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU4766596A (en) * 1995-01-31 1996-08-21 Eli Lilly And Company Ob gene product antibodies
PT866720E (pt) * 1995-11-22 2004-06-30 Amgen Inc Proteina ob para aumentar a massa do tecido mole
WO1997020933A2 (en) * 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
JPH09176198A (ja) * 1995-12-28 1997-07-08 Kikkoman Corp 抗肥満タンパク質モノクローナル抗体及びハイブリドーマ
WO1997026916A1 (en) * 1996-01-25 1997-07-31 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
EP0827750A3 (de) * 1996-08-23 2002-11-20 Eli Lilly And Company Formulierungen des Obesitäts-Proteins
WO1999023115A1 (en) * 1997-10-31 1999-05-14 Eli Lilly And Company Glycosylated obesity protein analogs
ATE280588T1 (de) * 1998-08-10 2004-11-15 Amgen Inc Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility

Also Published As

Publication number Publication date
PT1151102E (pt) 2006-07-31
DE60027409T2 (de) 2007-04-12
JP4841037B2 (ja) 2011-12-21
CY1107470T1 (el) 2012-12-19
AU781460B2 (en) 2005-05-26
EP1151102A1 (de) 2001-11-07
DE60027409D1 (de) 2006-05-24
CA2359840A1 (en) 2000-08-17
JP2002536018A (ja) 2002-10-29
AU3362300A (en) 2000-08-29
CA2359840C (en) 2012-10-23
EP1151102B1 (de) 2006-04-19
DK1151102T3 (da) 2006-05-29
ES2257287T3 (es) 2006-08-01
WO2000047741A1 (en) 2000-08-17

Similar Documents

Publication Publication Date Title
CY1107470T1 (el) Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι
AU2001254624A1 (en) Human coagulation factor vii variants
BRPI0410164A (pt) composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
CY1112655T1 (el) Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις
EP1484339A3 (de) Kallikreinhemmende "Kunitz-Domäne"Proteine dafür kodierende Nukleinsäure
YU48703A (sh) Novi interferonu beta-slični molekuli
HUP0001153A2 (hu) Kémiailag módosított polipeptidek, eljárás ezek előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
WO2002060955A3 (en) Modified antibodies and methods of use
DE60307701D1 (de) Mannose-Bindungsprotein enthaltende pharmazeutische Zusammensetzungen
HUP0103758A2 (hu) Neurotróf faktorok
EP0797999A3 (de) Fettleibigkeitprotein-Formulierungen
CY1111431T1 (el) Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων
WO1995025171A3 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
WO2003033658A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
HUP0500637A2 (hu) Neublasztin polimer konjugátumai és alkalmazási eljárásai
IL81221A0 (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for preparing said proteins and pharmaceutical compositions containing them
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
EP0369816A3 (de) Gegen menschliches polymorphes epitheliales Muzin spezifische monoklonale Antikörper
FI964186A0 (fi) Ei-liittävät gp350/220-variantit
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
CA2002833A1 (en) Interferon-gamma binding proteins
WO2002007514A3 (en) Glycosylated vegf-b and method for increasing the amount of soluble vegf-b
DE69529235T2 (de) Menschliche dnase i varianten
UA81601C2 (ru) Полипептид фактора vii и его применения для лечения случаев кровотечения или усиление нормальной системы кровоостановки

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1151102

Country of ref document: EP